- Home
- GENC vs DRTS Comparison
GENC vs DRTS Comparison
Compare GENC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- DRTS
- Stock Information
- Founded
- GENC 1894
- DRTS 2015
- Country
- GENC United States
- DRTS Israel
- Employees
- GENC N/A
- DRTS N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- DRTS Medical/Dental Instruments
- Sector
- GENC Industrials
- DRTS Health Care
- Exchange
- GENC Nasdaq
- DRTS Nasdaq
- Market Cap
- GENC 215.0M
- DRTS 252.8M
- IPO Year
- GENC N/A
- DRTS N/A
- Fundamental
- Price
- GENC $15.06
- DRTS $3.08
- Analyst Decision
- GENC
- DRTS Strong Buy
- Analyst Count
- GENC 0
- DRTS 2
- Target Price
- GENC N/A
- DRTS $8.00
- AVG Volume (30 Days)
- GENC 27.8K
- DRTS 36.7K
- Earning Date
- GENC 08-08-2025
- DRTS 08-13-2025
- Dividend Yield
- GENC N/A
- DRTS N/A
- EPS Growth
- GENC N/A
- DRTS N/A
- EPS
- GENC 0.99
- DRTS N/A
- Revenue
- GENC $113,166,000.00
- DRTS N/A
- Revenue This Year
- GENC N/A
- DRTS N/A
- Revenue Next Year
- GENC N/A
- DRTS N/A
- P/E Ratio
- GENC $15.34
- DRTS N/A
- Revenue Growth
- GENC 7.70
- DRTS N/A
- 52 Week Low
- GENC $10.80
- DRTS $1.93
- 52 Week High
- GENC $24.88
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- GENC 58.37
- DRTS 59.10
- Support Level
- GENC $14.72
- DRTS $3.12
- Resistance Level
- GENC $15.17
- DRTS $3.35
- Average True Range (ATR)
- GENC 0.68
- DRTS 0.15
- MACD
- GENC 0.03
- DRTS 0.02
- Stochastic Oscillator
- GENC 86.62
- DRTS 70.00
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.